EADO/WCM 2025 | Japanese and East Asia-specific guidelines for the management of melanoma
Satoshi Fukushima, MD, PhD, Kumamoto University, Kumamoto, Japan, discusses differences in melanoma subtype and drug efficacy between Western countries and East Asia, highlighting the need for region-specific guidelines. Dr Fukushima notes that meta-analysis from Japanese retrospective observational study yielded different results, concluding that dual checkpoint blockade does not extend overall survival and are outweighed by adverse effects, recommending PD-1 monotherapy as a first-line treatment for BRAF wild-type melanoma in Japan. This interview took place at the 11th World Congress of Melanoma and 21st EADO Congress in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
